A previous clinical study for advanced NSCLC demonstrated that an extended PPS in first‐line monotherapy and a molecule targeting agent were associated with good PS.10 However, the factors affecting PPS in individual cases with EGFR‐mutated NSCLC treated with first‐line EGFR‐TKI are obscure. This evidence concerns the gene EGFR and non-small cell lung carcinoma.